Goldline Pharmaceutical Limited Links 
Allotment
Goldline Pharmaceutical IPO will open for subscription on May 12, 2026 and the public issue will close on May 14, 2026. The IPO is launched through the Book Build Issue route. The company plans to mobilize nearly ₹11.61 crores through this offering, entirely consisting of a fresh issue of ₹11.61 crores along with an offer for sale of up to [.] equity shares having a face value of ₹10 each.
The price band for the Goldline Pharmaceutical IPO has been fixed at ₹41 to ₹43 per equity share. The issue allocation is divided into 35% for retail investors, 50% for QIBs, and 15% for HNI investors. The shares are proposed to be listed on BSE SME on May 19, 2026, while the basis of allotment is likely to be finalized on May 15, 2026.
In terms of financial performance, the company recorded revenue of ₹28.06 crores in 2025 compared to ₹23.57 crores in 2024. Net profit increased to ₹2.83 crores in 2025 from ₹1.81 crores in 2024. Based on the company’s improving financial growth and profitability, investors may consider this IPO for long-term investment opportunities.
₹43
0%
Open
₹43
HIgh - Low
₹43
Previous Close
₹43
Total Traded Value
0
52 Weeks High
₹43
52 Weeks Low
₹43
Updates On
May 01, 2026
IPO. Open
May 12, 2026
IPO. Close
May 14, 2026
IPO. Price
₹43.00
IPO Market price
₹41.28 Cr
IPO Details
| IPO Date | 19 May |
| IPO Listing Date | 19 May |
| IPO Face Value | ₹10 Per Equity Share |
| IPO Price Range | ₹43.00 |
| IPO Issue Size | Approx ₹12 Crores |
| IPO Sale Type | Fresh Capital |
| Employee Discount | - |
| IPO Issue Type | Book build Issue |
| IPO Listing | BSE SME Platform |
| hare Holding Pre Issue | 69,00,000 shares |
IPO Timeline
| IPO Open Date | 12 May |
| IPO Close Date | 14 May |
| IPO Allotment (Tentative) | 15 May |
| Refunds | 18 May |
| Credit to Demat Account | 18 May |
| IPO Listing Date | 19 May |
IPO Reservation
| Category | Offer |
|---|---|
| QIB Shares Offered | 5,40,000 Shares |
| NII (HNI) Shares Offered | 3,90,000 Shares |
| Retail Shares Offered | 9,00,000 Shares |
IPO Lot Size
Investors are required to apply for a minimum of 2,400 equity shares, and bids must be placed in multiples of 1,200 shares thereafter.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 6,000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
Goldline Pharmaceutical Ltd. is a rapidly growing pharmaceutical company headquartered in Nagpur, Maharashtra. Established on 28 February 2005 by Mr. Amol Mujumdar, the company has expanded its operations across multiple Indian states including Maharashtra, Chhattisgarh, Madhya Pradesh, Odisha, Tamil Nadu, Rajasthan, Jharkhand, Goa, and Bihar. The company focuses on delivering quality therapeutic products while maintaining strong customer relationships and market-driven business practices. Its expanding product portfolio and innovative formulations have helped build a strong presence in the pharmaceutical sector.
Goldline Pharmaceutical operates with a dedicated marketing, product management, and field force team focused on sustainable business growth. The company continuously updates its product range with advanced formulations and brand extensions to meet changing healthcare demands. With a strong emphasis on employee development, operational efficiency, and customer satisfaction, Goldline Pharmaceutical aims to strengthen its market position and continue its expansion across India.
Company Financials (Consolidated)
| Assets | 27.4 | 26.28 | 22.93 |
| Total Income | 21.41 | 28.06 | 23.57 |
| Profit After Tax | 2.22 | 2.83 | 1.81 |
| EBITDA | 4.16 | 5.83 | 4.3 |
| Net Worth | 12.36 | 10.35 | 7.86 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 |
| Total Borrowing | 9.47 | 11.03 | 11.13 |
Key Performance Indicator (KPI)
| ROE | 35.84% |
| ROCE | 38.46% |
| Debt/Equity | - |
| RoNW | 27.37% |
| PAT Margin | 10.10% |
| EBITDA Margin | 20.79% |
| Price to book value | - |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | - |
| 2 | To meet out the expenses of Working Capital Requirement | - |
| 3 | To meet out the General Corporate Purposes; | - |
| 4 | Offer for Sale (OFS) | - |
Contact Details
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/
Detail Registrar
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Compare: